Suvranu Ganguli

Dr. Suvranu Ganguli

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
SGSuvranu Ganguli
Suvranu Ganguli
RLRaymond Lareau
Raymond Lareau
TJTim Jarrett
Tim Jarrett
MSMichael C. Soulen
Michael C. Soulen
A novel aqueous-based liquid embolic (Hydrogel Embolic System, HES) has been developed to embolize hypervascular tumors by filling the tumor vascular bed and solidifying into a hydrogel. HES was evaluated for embolization safety and efficacy relative to microspheres in a preclinical rabbit kidney model. A renal embolization model in New Zealand white rabbits was utilized. Twenty-four rabbits underwent unilateral kidney embolization via the main renal artery with either HES or 40 μm microspheres. Twenty-two rabbits survived the procedure and were monitored for 2, 12, 17.5 or 26 weeks prior to sacrifice. All rabbits underwent a repeat renal angiogram prior to necropsy. HES was evaluated for non-target embolization, safety, and embolization effectiveness as measured by recanalization and viability of embolized tissue. Both embolization materials were found to be safe, with targeted tissue necrosis and absence of non-target embolization. Pre-necropsy angiograms found vascular recanalization in 0/14 (0%) HES embolized kidneys, and in 3/8 (38%) microsphere embolized kidneys (p = 0.036). Viable kidney tissue was observed in 2/14 (14%) kidneys embolized with HES and 5/8 (63%) kidneys embolized with microspheres (p=0.052). All kidneys embolized with microspheres that showed vascular recanalization had viable tissue on histological sections. HES was observed in vessels as small as 10μm in diameter in histological analysis. HES provided deep, durable vascular bed embolization that resulted in less recanalization and on average less viable target tissue compared to 40 μm microspheres. No systemic effects or non-target tissue embolization was identified.

17 October 2020 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
JLJiangtao Liu
Jiangtao Liu
EWEric Paul Wehrenberg-Klee
Eric Paul Wehrenberg-Klee
EBEmily D. Bethea
Emily D. Bethea
RURaul N. Uppot
Raul N. Uppot
KYKei Yamada
Kei Yamada
SGSuvranu Ganguli
Suvranu Ganguli
Introduction. Hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunt (TIPS) placement remains a leading adverse event. Controversy remains regarding the optimal stent diameter given that smaller stents may decrease the amount of shunted blood and decrease the risk of HE, but stent patency and/or clinical adequacy of portal decompression may also be affected. We aim to provide meta-analysis-based evidence regarding the safety and efficacy of 8 mm vs. 10 mm stents during TIPS placement. Methods. PubMed, Embase, Cochrane Library, and Web of Science were searched for studies comparing 8 mm and 10 mm stents during TIPS placement for portal hypertension decompression in cirrhotic patients. Randomized controlled trials and cohort studies were prioritized for inclusion. Overall evaluation of quality and bias for each study was performed. The outcomes assessed were the prevalence of HE, rebleeding or failure to control refractory ascites, and overall survival. Subgroup analysis based on TIPS indication was conducted. Results. Five studies with a total number of 489 cirrhotic patients were identified. The pooled hazard ratio (HR) of post-TIPS HE was significantly lower in patients in the 8 mm stent group than in the 10 mm stent group (HR: 0.68, 95% CI: 0.51~0.92, value < 0.0001). The combined HR of post-TIPS rebleeding/the need for paracentesis was significantly higher in patients in the 8 mm stent group than in the 10 mm stent group (HR: 1.76, 95% CI: 1.22~2.55, value < 0.0001). There was no statistically significant difference in the overall survival between the 8 mm and 10 mm stent groups. The combined risk of HE in the variceal bleeding subgroup was statistically lower (HR: 0.52, CI: 0.34-0.80) with an 8 mm stent compared with a 10 mm stent. The combined risk of both rebleeding/paracentesis and survival was not statistically significant between 8 mm and 10 mm stent use in subgroup analysis. Conclusion. 8 mm stents during TIPS placement are associated with a significant lower risk of HE compared to 10 mm stents (32% decreased risk), as well as a 76% increased risk of rebleeding/paracentesis. Meta-analysis results suggest that there is not one superior stent choice for all clinical scenarios and that the TIPS indication of variceal bleeding or refractory ascites might have different appropriate selection of the shunt diameter.

1 May 2021 in Brachytherapy
Verified
Journal Article
Closed access
KHKelvin Hong
Kelvin Hong
OAOlaguoke Akinwande
Olaguoke Akinwande
LBLisa Bodei
Lisa Bodei
MCMurthy Rk. Chamarthy
Murthy Rk. Chamarthy
PDPhillip M. Devlin
Phillip M. Devlin
CTClayton K. Trimmer
Clayton K. Trimmer

5 March 2021 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
NFNathan E. Frenk
Nathan E. Frenk
TBTeodora Bochnakova
Teodora Bochnakova
SGSuvranu Ganguli
Suvranu Ganguli
NMNathaniel Mercaldo
Nathaniel Mercaldo
AAAndrew S. Allegretti
Andrew S. Allegretti
KYKei Yamada
Kei Yamada
Maximally decreasing portal pressures with transjugular intrahepatic portosystemic shunt (TIPS) is associated with improved ascites control but also increased encephalopathy incidence. Since splenic venous flow contributes to portal hypertension, we assessed if combining small-diameter TIPS with splenic artery embolization could improve ascites while minimizing encephalopathy. Fifty-five patients underwent TIPS creation for refractory ascites. Subjects underwent creation of 8 mm TIPS followed by proximal splenic artery embolization (group A, n=8), or of 8 mm (group B, n=6) or 10 mm TIPS (group C, n=41) without splenic embolization. Data were retrospectively reviewed. In group A, median portosystemic gradient decreased from 19 mmHg to 9 mmHg after TIPS, and 8 mmHg after subsequent splenic artery embolization. In groups B and C, gradient decreased from 15 mmHg to 8 mmHg and 16 mmHg to 6 mmHg. All patients except for one in group A and two in C had greater than 50% reduction in the number of paracenteses in 3 months. Any postprocedural encephalopathy incidence was 62%, 50%, 83% in groups A, B, and C, respectively. Overall, 20% of subjects with 10 mm TIPS required TIPS reduction/closure compared to 7% of subjects with 8 mm TIPS. We found that 8 mm diameter TIPS provided similar ascites control compared to 10 mm TIPS regardless of splenic embolization. While more patients with 10 mm TIPS required reduction/closure for severe encephalopathy, the study was underpowered for definitive assessment. Splenic embolization might have the potential to further decrease portosystemic gradient and ascites as an alternative to dilation of TIPS to 10 mm minimizing the risk of encephalopathy, but larger studies are warranted.

23 January 2023 in American Journal of Interventional Radiology
Verified
Journal Article
Open access
VSVirginia H. Sun
Virginia H. Sun
DCDenston E. Carey
Denston E. Carey
ASAvik Som
Avik Som
JCJohn Di Capua
John Di Capua
DDDania Daye
Dania Daye
SGSuvranu Ganguli
Suvranu Ganguli
Objectives: The purpose of this study is to compare the role of bronchial artery embolization (BAE) in hemoptysis due to malignant and non-malignant etiologies. Material and Methods: Data from patients who underwent BAE at a tertiary care center from October 2002 to 2018 were retrospectively reviewed. Variables evaluated include procedural indication, technical success, clinical success, re-embolization, intensive care unit (ICU) admission, length of stay, and thirty-day readmission. Categorical and continuous variables were analyzed using Pearson’s Chi-squared and two sample t-tests, respectively. Post-procedure survival and re-embolization were analyzed using Kaplan–Meier curves and Cox proportional hazard models. Results: 114 BAE procedures from 93 unique patients with hemoptysis were identified, with 29.8% of procedures being performed for hemoptysis secondary to malignancy and 70.2% for benign causes. The technical and clinical success rates of the procedure were similar between benign and malignant etiologies (benign/malignant: 92.5% vs. 91.2% and 82.5% vs. 73.5%, respectively). There were no statistically significant differences in rates of need for re-embolization, ICU admission, 30-day readmission, mean hospital length of stay, or mortality between benign and malignant groups. Clinically successful embolization was protective against death (HR = 0.19, P < 0.001) and re-embolization (HR = 0.04, P = 0.001), while higher American Society of Anesthesiologists’ (ASA) score, female sex, and primary pulmonary malignancy were associated with risk of death. Conclusion: While patients with a malignant cause of hemoptysis had an increased risk of mortality and decreased survival time, BAE for malignant hemoptysis is effective with outcomes comparable to that for benign hemoptysis as indicated by high clinical and technical success rates and low rates of re-embolization.

9 June 2021 in Digestive Disease Interventions
Verified
Journal Article
Closed access
PDF file
RGRipal T Gandhi
Ripal T Gandhi
SGSuvranu Ganguli
Suvranu Ganguli
Over the last decade, Yttrium-90 radioembolization has advanced as a treatment for primary and secondary liver tumors in many ways, including better patient selection, improvements in technique, mitigation of complications, dose optimization, and implementation of post treatment imaging including voxel-based dosimetry. With the rapid growth of literature dedicated to radioembolization along with substantial progress in systemic therapies, it can be challenging to stay up to date with clinical decisions, techniques, and management algorithms regarding best practice for different disease entities. This issue of DDI is dedicated to the science and evidence as well as the experience of experts regarding radioembolization. While radioembolization was initially considered a palliative treatment for primary and metastatic malignancies, its role has expanded significantly. For hepatocellular carcinoma, for example, there is now data to support treating early disease, including serving as a neoadjuvant therapy to induce hepatic hypertrophy prior to resection, bridging and downstaging patients to liver transplantation, and even curing certain patients via radiation segmentectomy. The advent of immuno-oncology has emerged as a significant advancement in cancer care, and research with immune check-point inhibitors is thriving. Our understanding of combining immunotherapies with locoregional therapies like radioembolization is rudimentary at best. The holy grail in immuno-oncology is the potential to induce an abscopal response; combining immunotherapeutics with Y90 has the potential to enhance antitumor immune response, which needs to be proven through well-conducted clinical trials. Within this issue, we have articles reviewing product specification and patient selection, radioembolization related to specific disease processes such as metastatic colorectal cancer and breast cancer, and a systemic review of radiation-based therapies for hepatocellular carcinoma. We also have articles addressing where radioembolization is heading, with articles on office-based radioembolization, radioembolization outside the liver, and the status of Holmium-166 radioembolization. Yttrium-90 radioembolization continues to evolve and we realize that this issue is by no means comprehensive. We hope that the articles within provide the reader important updates and encourage further research in this exciting field to ultimately improve the outcomes for our patients. Publication Date: 09 June 2021 (online) © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA